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Abstract
Quantifying oxygenation in viable tumor remains a major obstacle toward a better understanding of the tumor micro-
environment and improving treatment strategies. Current techniques are often complicated by tumor heterogeneity.
Herein, a novel in vivo approach that combines 19F magnetic resonance imaging (19F-MRI) R1 mapping with diffusion-
based multispectral (MS) analysis is introduced. This approach restricts the partial pressure of oxygen (pO2) measure-
ments to viable tumor, the tissue of therapeutic interest. The technique exhibited sufficient sensitivity to detect a
breathing gas challenge in a xenograft tumor model, and the hypoxic region measured by MS 19F-MRI was strongly
correlated with histologic estimates of hypoxia. This approach was then applied to address the effects of antivascular
agents on tumor oxygenation, which is a research question that is still under debate. The technique was used to
monitor longitudinal pO2 changes in response to an antibody to vascular endothelial growth factor (B20.4.1.1) and
a selective dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor (GDC-0980). GDC-0980 reduced
viable tumor pO2 during a 3-day treatment period, and a significant reduction was also produced by B20.4.1.1. Overall,
this method provides an unprecedented view of viable tumor pO2 and contributes to a greater understanding of the
effects of antivascular therapies on the tumor’s microenvironment.
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Introduction
Regional hypoxia is one of the most important factors regulating
tumor growth as well as influencing the clinical outcome after thera-
peutic intervention [1,2]. Assessing tumor regional hypoxia quantita-
tively, both spatially and temporally, is challenging because of the need
for a noninvasive technique and the complications arising from hetero-
geneity in tumor morphometry. A number of techniques have been
developed in an effort to better visualize tumor hypoxia, either by
detecting the presence of hypoxic cells or quantitatively measuring
the partial pressure of oxygen (pO2) [3]. Hypoxic cells can be detected
immunohistochemically or by positron emission tomography in which
2-nitroimidazole–like imaging markers covalently bind to hypoxic
cells. However, these methods are single time-point measurements
and are dependent on a biochemical reaction. Direct pO2 measure-
ments can be achieved by several techniques that each face individual
limitations: polarographic electrodes invasively measure oxygenation in
the local tissue around the electrode; optical measurements are severely
limited by penetration depth; Overhauser imaging and electron para-
magnetic resonance imaging are not as readily available to most re-
search groups as alternative imaging approaches, such as magnetic
resonance imaging (MRI) [3]. 19F-MRI oximetry [4–7], which uses
perfluorocarbon (PFC) emulsions as an imaging contrast agent, is a
noninvasive method that can map tumor pO2 in vivo. Compared to
1H-MRI pO2 techniques [8,9],
19F-MRI has no background signal
resulting in a pO2 signal that is specific to the contrast agent. Given
that PFCs are well tolerated in animals and are highly stable in tissue,
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the use of PFCs allows repeated measurements [10]. The underlying
principle is that the spin-lattice, or longitudinal, relaxation rate (R1)
of certain PFCs is a linear function of oxygen levels at a given tem-
perature. Therefore, the power of 19F-MRI oximetry is that the pO2
measurement is independent of the absolute 19F signal intensity (PFC
uptake). Taken together, 19F-MRI can provide a direct noninvasive
oxygen measurement [4–7].
Unfortunately, all of these attempts to measure tumor oxygenation
suffer from the confounding effects of tumor heterogeneity. Regional
hypoxia, associated with the spatial heterogeneity of tumor perfusion
and metabolism, contributes to the heterogeneous tissue morphology
of solid tumors [2,11]. Tumor heterogeneity can complicate the
quantification of tissue pO2 for a number of reasons, including the
following: sampling errors associated with point measurements (e.g.,
polarographic electrodes), variability in the distribution of the contrast
agent, and the inclusion of nonviable tumor regions in whole-tumor
estimates. To address tumor heterogeneity, Carano et al. developed a
diffusion-based multispectral (MS) technique to distinguish regions of
viable tumor, necrosis, and subcutaneous adipose tissue based on the
apparent diffusion coefficient (ADC), spin-spin relaxation time (T 2),
and proton density (M0) [12]. Specifically, the viable tumor, the tissue
of therapeutic interest, was previously found to be well correlated with a
histologic estimate of viable tumor [12].
A novel approach that combines 19F-MRI R1 mapping with a
diffusion-based MS analysis approach as a means to spatially map
in vivo pO2 in the viable tumor, the tissue of therapeutic interest, is
presented in this manuscript. Using a breathing gas challenge experi-
ment, it is shown that pO2 measurements can be restricted to the viable
tumor, the most relevant area of the tumor rather than including the
necrotic areas as occurs with whole-tumor estimates.
The ultimate goal of developing this approach is to study hypoxia in
the tissue of therapeutic interest (viable tumor) during tumor progres-
sion and to monitor the response to treatments. Specifically, the effects
of antivascular agents on tumor oxygenation have been in question for
a number of years, where differing responses for tumor pO2 have been
reported [11,13–16]. To address this question, an antibody that blocks
both murine and human vascular endothelial growth factor A (VEGF-A;
B20.4.1.1) was evaluated byMS 19F-MRI. B20.4.1.1 has been previously
shown to reduce vascular density [17] and, thus, may alter O2 supply
through this mechanism. Furthermore, a novel dual phosphoinositide
3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor,
GDC-0980, that potentially could affect both O2 supply and con-
sumption was evaluated. The PI3K/mTOR pathway is a key signaling
pathway in human cancer. The pathway not only plays an important
role in tumor cell signaling, which affects O2 consumption, but also is a
key component of VEGF receptor 2 intracellular signaling in vascular
endothelial cells, which can affect O2 supply [17]. The potent and se-
lective dual PI3K/mTOR inhibitor, GDC-0980, has been shown to pro-
duce a strong and rapid antivascular response in murine xenograft tumor
models [17]. However, the effects of dual PI3K/mTOR inhibition on
tumor oxygen level remain unknown. Given that GDC-0980 has en-
tered clinical development [18], it will be valuable to ascertain
the tumor metabolic changes associated with PI3K/mTOR inhibition.
Materials and Methods
PFC Emulsion Preparation
Perfluoro-15-crown-5-ether (SynQuest Laboratories, Inc, Alachua,
FL) was mixed with an emulsifying solution of lecithin soy (MP
Biomedicals, Solon, OH) and lactated Ringers solution (Baxter,
Deerfield, IL). The mixture was processed using a microfluidizer (LV1;
Microfluidics, Newton, MA) at 30,000 psi to form emulsions with a
mean diameter of 250 nm, as measured by dynamic light scattering
(DynaPro Nanostar; Wyatt Technology, Santa Barbara, CA). The final
concentration of perfluoro-15-crown-5-ether was 60% wt/vol. The PFC
solutions were then sterilized by microfiltration using membrane filters
with a pore size of 0.45 μm (Thermo Scientific, Waltham, MA) and
adjusted to a pH of 7.4.
Animal Preparation
The Institutional Animal Care and Use Committee at Genentech Inc
(South San Francisco, CA) approved all animal protocols in this study.
Female athymic nude mice (n = 50, 20-25 g; Harlan Laboratories,
Indianapolis, IN) were inoculated subcutaneously on the hindlimb
with HM-7 colorectal cancer cells (3.5 × 106 cells per mouse). The
animals that were used in the study had an approximate tumor volume
range of 150 to 250 mm3 (volume = 0.5 × length × width2) at the
time when the animals entered the study. Animals were injected intra-
venously (i.v.) with 400 μl of the PFC solution at 48 hours and, again,
at 24 hours before MRI.
Mice were placed under anesthesia by administration of 2% iso-
flurane in a warm anesthesia induction box and then placed in a
custom-built animal holder and moved to the magnet bore, where anes-
thesia was maintained with 1% to 2% isoflurane that was adjusted
according to the respiration rate of the animal. The animals’ breathing rate
was monitored, and temperature was maintained at 37°C using warm air-
flow controlled by a LabVIEW software module with feedback provided
by a rectal temperature probe (SA Instruments, Stony Brook, NY).
MRI Measurements
Experiments were performed on a 9.4-T Agilent MRI System
equipped with a 1H/19F 10-mm surface coil (Agilent Technologies Inc,
Santa Clara, CA). 1H-MRI measurements were performed first.
Twelve 1-mm-thick coronal slices were acquired (field of view = 25.6 ×
25.6 mm, matrix = 64 × 64). A diffusion-weighted fast spin-echo multi-
slice (FSEMS) sequence was used to calculate an ADC spatial map with
the following parameters: six b values ranging from 270 to 1000 s/mm2,
repetition time (TR) = 3 seconds, echo train length = 4, echo spacing =
3.95 milliseconds, number of averages (NA) = 2, diffusion gradient
separation (Δ) = 30 milliseconds, duration (δ) = 3.3 milliseconds, result-
ing in a total scan time of 9 minutes. A spin echo multislice (SEMS)
sequence was used to generate T 2 and M0 maps that employed the
following parameters: echo times = 5, 26, 47, and 68 milliseconds,
TR = 3 seconds, NA = 1, and a scan time of 12 minutes. Spatial maps
of ADC were obtained from the diffusion data by applying a linear least-
squares regression to the natural logarithm of the signal intensity.
Similarly, T 2 maps were obtained from the T 2-weighted, spin-echo data
by a linear least-squares regression [12].
19F-MRI was then carried out (field of view = 25.6 × 25.6 mm,
matrix = 32 × 32, zero-filled to 64 × 64). A 19F-weighted SEMS
sequence was used to obtain a fluorine anatomic reference image
(TR = 5 seconds, echo time = 8.5 milliseconds, NA = 4, scan time
of 10 minutes). A 19F single-shot, inversion recovery FSEMS sequence
was employed to generate spatial maps of R1 [FSEMS, inversion times
(TI) = 0.1, 0.3, 0.5, 0.6, 0.7, 0.9, 1.2, 1.8, and 2.5 seconds; TR =
6 seconds, echo spacing = 4.1 milliseconds, echo train length = 32,
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NA = 32, a scan time of 29 minutes]. Then, the R1 of the
19F nucleus
was calculated by using the following equation [19]:
IðTIÞ = I0  1 a  eR1 TI
 
; ð1Þ
where I(TI) is the signal intensity at time TI, I0 is the signal intensity at
equilibrium magnetization, a is a coefficient, and R1 is the spin-lattice
relaxation rate. R1, a, and I0 are determined from Equation 1 using a
nonlinear regression algorithm.The pO2was then determined according
to the calibration curve between R1 and pO2. The calibration curve was
obtained by measuring the R1 of PFC phantoms at known concentra-
tions of dissolved oxygen (0%, 10%, 21%, 60%, and 100%). Twenty-
one percent of oxygen corresponds to 160mmHg, and 100% of oxygen
corresponds to 760 mm Hg. Phantoms were prepared in triplets.
MS Analysis
MS analysis of the 1H data was used for tissue segmentation.
K -means (KM) clustering was performed using the ADC, proton
density, and T 2 maps as previously described [12,20,21]. The KM
algorithm segmented the tumors into the following four tissue classes:
viable tumor tissue, subcutaneous adipose tissue, low-T 2 necrotic class,
and high-ADC necrotic class. The low-T 2 necrotic class represents an
area of necrosis with active or recent hemorrhage, and the high-ADC
necrotic class has been found to represent an acellular “cyst-like” region
[12]. The tissue class map was combined with the 19F pO2 map to
estimate pO2 in the four tissue classes.
Histologic Analysis
After the final imaging time point, the animals were injected
intraperitoneally (20 mg/kg) with hypoxyprobe (Hypoxyprobe Inc,
Burlington, MA) 1 hour before being killed by cervical dislocation
under anesthesia. The tumors were extracted and fixed in 10% neutral
buffered formalin solution. Hematoxylin and eosin, MECA-32, and
hypoxyprobe stains were used to identify tissue architecture, blood
vessels, and hypoxic cells, respectively. The histologic hypoxic region
was identified by hypoxyprobe staining that is typically considered to
label cells present in a hypoxic environment where the pO2 is between
0 and 10 mm Hg [22]. Histologic viable tumor tissue was identified
by hematoxylin and eosin staining.
Whole slide images were acquired by the Olympus Nanozoomer
automated slide scanning platform (Hamamatsu, Bridgewater, NJ) at
×200 final magnification. Scanned slides were analyzed in the Matlab
software package (version R2011b by MathWorks, Natick, MA) as
24-bit RGB images. Various tumor regions (viable area, necrotic area,
hypoxyprobe positive) were identified using a combination of support
vector machines (SVMs) [23] and genetic programming [24]. A train-
ing set of representative areas was first generated manually and assigned
a binary classification (positive for the region of interest or negative
for regions to exclude). Then, an SVM was trained using RGB and
texture values from these selections. Application of this SVM resulted
in a binary image for each selection, and the noise in the resulting
images was removed through the application of genetic programming,
which found a sequence of simple morphologic operators that maxi-
mized the solution accuracy for both positive and negative selections,
which was then applied to the entire image.
The analysis of vascular density was restricted to viable tumor tissue.
A segmentation algorithm uses a sequence of morphologic operations
to consolidate MECA-32–stained areas into individual vessels. The
identification of vessels was aided by including vessel lumens, as char-
acterized by empty white spaces that are adjacent to MECA-32–stained
regions. Size and shape-based filtering of the resulting objects was
used to remove noise. The vessel density here was defined as the vessel
perimeter divided by the viable tumor area (mm−1). Similarly, the
percent hypoxic fraction was measured as the hypoxyprobe stain–
positive area divided by the viable tumor area (%).
Experimental Protocols
Validation study. In the validation study, the first group of mice
(n = 10) received two consecutive 19F R1 measurements acquired
at normoxia (21% O2) to assess the intrasessional reproducibility
of the pO2 measurement. For a second group of mice (n = 20),
19F R1 maps were acquired at normoxia (21% O2) and during hyper-
oxia (carbogen: 95% O2, 5% CO2) conditions, which were done
sequentially by changing the breathing gas. A 10-minute gap was
employed between the two acquisitions to allow for the blood oxygena-
tion to reach equilibrium, where the blood oxygen saturation was
continuously monitored by the O2C System (LEA Medizintechnik
GmbH Inc, Giessen, Germany) on the hind footpad of the animal.
The MS estimates of the hypoxic region (0 < pO2 < 10 mm Hg) in
viable tumor tissue were compared with the histologic estimates of
hypoxia (hypoxyprobe analysis).
Treatment studies. Treatment studies were performed in two
additional cohorts of mice. In the first treatment study, B20.4.1.1 treat-
ment (10 mg/kg, n = 13) or a control IgG (n = 11) was administrated
as a single i.v. dose. Imaging was performed pretreatment (day 0) and
24 hours posttreatment (day 1). In the second study, B20.4.1.1
(10 mg/kg, n = 10) was administered as a single i.v. dose after pre-
treatment imaging on day 0. In the second group, GDC-0980
(10 mg/kg, n = 10) was administered orally daily on days 0, 1, and 2.
For the control group (n = 10), a control IgG and 0.5%methycellulose/
0.2% Tween 80 were used as controls for B20.4.1.1 and GDC-0980,
respectively. Imaging was performed on day 0, 1, 2, and 3.
Statistical Analysis
Statistical significance was defined as P < .05. To compare two
groups, an unpaired t test was used. To compare pretreatment to
posttreatment data within a group, a paired t test was used. Statistical
analysis was performed with JMP 9 (SAS Institute, Cary, NC) and
Excel 2010 (Microsoft Inc, Redmond, WA). Data are presented as
means ± standard error.
Results
Reproducibility of In Vivo MS 19F-MRI
The uptake of the PFCs was significant but variable within the
tumor (Figure 1, A and B). A very strong 19F signal was visualized
within some areas of the viable tissue class (Figure 1, B and C), con-
sistent with the presence of vessels in these regions. In addition, strong
19F uptake was observed in the low-T 2 necrosis class (Figure 1B, green
arrows), where leakage is likely due to hemorrhage. This class has been
found histologically to contain intact RBCs that shorten the T 2 and is
likely an area of recent or active hemorrhage [12].
The 19F R1 maps of PFC calibration samples were obtained, and
these data were then used to estimate pO2 for all studies according
to the measured linear relationship between R1 and the oxygen level
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[R1 = 0.0246 * O2 (%) + 0.7473, R
2 = 0.999; Figure W1]. To test
the intrasessional reproducibility of pO2 measurements, two
19F R1
mapping acquisitions were made under normoxia (Figure 2A). The
mean pO2 values of the two acquisitions for each of the four classes
are given as follows: viable tumor class, 51.92 ± 9.21 and 56.22 ±
9.24 mm Hg (P = .42); adipose tissue class, 55.16 ± 9.87 and
52.45 ± 9.71 mm Hg (P = .59); low-T 2 necrosis class, 53.26 ±
12.91 and 55.27 ± 15.07 mm Hg (P = .82); high-ADC necrosis class,
44.35 ± 17.23 and 33.42 ± 10.90 mm Hg (P = .84). The repetitive
measurements revealed no significant change of mean pO2 over time
in all four tissue classes (P > .05, paired t test). The overall tumor
response is a weighted average of all four tissue classes; therefore,
the overall tumor did not exhibit a difference between the two mea-
surements (49.98 ± 9.16 and 51.96 ± 9.53 mm Hg, P = .50; Fig-
ure 2A). An example of consecutive pO2 estimates of the same tumor
are shown in Figure 2B.
MS 19F-MRI Detects pO2 Increase in Viable Tumor due
to Carbogen Challenge
To test the hypothesis on tumor heterogeneity and pO2 response, a
second group of mice underwent a carbogen breathing gas challenge.
Two measurements were made under normoxia and hyperoxia, re-
spectively. Under the breathing gas challenge, there was a hetero-
geneous response within the tumor (Figure 3). Statistical analysis
revealed that the viable tumor class (normoxia: 45.73 ± 4.30 mm Hg;
hyperoxia: 61.06 ± 5.98 mm Hg, paired t test, P = .018), adipose
tissue class (normoxia: 54.80 ± 5.75 mm Hg; hyperoxia: 65.71 ±
7.13 mm Hg, P < .01), and low-T 2 necrosis class (normoxia: 32.46 ±
5.98 mm Hg; hyperoxia: 44.64 ± 8.02 mm Hg, P < .01) exhibited
a significant increase in pO2 in response to hyperoxia challenge
(Figure 3A), where both viable regions (viable tumor and adipose
tissue) showed an increase in pO2 consistent with a vascularized tis-
sue. The increase in pO2 for the low-T 2 necrosis class provided further
evidence of active hemorrhage. The high-ADC necrosis class showed
no significant change in pO2 (normoxia: 34.37 ± 5.09 mm Hg;
hyperoxia: 43.44 ± 8.67 mmHg, P = .10), consistent with the acellular
“cyst-like” nature of the region [12]. An example of the response of a
tumor to the breathing gas challenge is shown in Figure 3B.
MS 19F-MRI In Vivo Estimate of Hypoxic Area Correlates
with Histologic Staining of Hypoxic Cells
The in vivo estimate of hypoxic area by MS 19F-MRI exhibited
a strong correlation (r = 0.79, P < .01) with the ex vivo estimate of
hypoxia derived from the hypoxyprobe stain–positive area histologic
analysis (Figure 4A). The MRI hypoxia region was defined as pO2
values between 0 and 10 mm Hg based on the in vivo pO2 maps
(Figure 4B, red). Histologically hypoxic (hypoxyprobe-positive) tissue
(Figure 4B, brown) corresponds to areas in which the cellular pO2 is
below 10 mm Hg. The histologic hypoxic area in viable tissue was
assessed in a centrally located section of each tumor (approximately
coplanar with the MRI plane) and was then compared with the
corresponding imaging slice in the in vivo MRI data.
MS 19F-MRI Detects Decrease of pO2 after Anti-VEGF
(B20.4.1.1) Treatment
In the first treatment study, the B20.4.1.1-treated group (Δday 1 − day 0 =
7.38 ± 7.53 mm3) at 24 hours posttreatment did not exhibit a signifi-
cant difference in viable tumor growth, identified by MS classification,
when compared with control (Δday 1 − day 0 = 19.07 ± 6.17 mm
3, P >
.05; Figure 5A). However, a significant reduction in pO2 was detected
Figure 1. Anatomic images of PFC uptake in an HM-7 xenograft tumor. (A) The 19F density images acquired in the same anatomic
locations with 1H density images reveal variable, albeit adequate PFC uptake. (B) A sample image of PFC uptake from the second slice
in A is highlighted in red. The PFC uptake was heterogeneous. Some areas showed strong uptake of PFCs in the center of the tumor
slice (green arrowheads). (C) The corresponding KM class map for the slice in B revealed that strong uptake of PFCs occurred in some
areas of viable tumor, some areas of adipose tissue, and the low-T 2 necrosis class.
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Figure 3. The change in mean pO2 under hyperoxia challenge for the MS tissue classes. (A) pO2 data were acquired under normoxia
(black) and once again under carbogen (95% O2, 5% CO2) breathing gas challenge (red). The pO2 in viable tumor class increased from
45.73 ± 4.30 to 61.06 ± 5.98 mm Hg, and the adipose tissue class and low-T 2 necrosis class also exhibited a significant increase of pO2.
The high-ADC necrosis class showed no change in pO2. The overall response is a weighted average of the four tissue classes. Data
are shown as means ± SEM. (B) An example of a pO2 spatial map response to hyperoxia challenge. There was a heterogeneous response
within the tumor, some areas increased dramatically, whereas other regions did not respond. *P< .05 and ***P< .001; NS, not significant.
Figure 2. Repeated pO2 measurements revealed no significant change over time in the HM-7 mouse xenograft tumor model. (A) Two
consecutive pO2 data sets were obtained under normoxia (black and blue). There was no significant change of mean pO2 over time in
all four tissue classes. The overall tumor response is a weighted average of all four tissue classes. Data are shown as means ± SEM.
(B) An example of a pO2 spatial map for the same tumor slice generated from the two consecutive measurements.
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within the viable tumor. The B20.4.1.1-treated group showed a reduc-
tion of viable tumor pO2 not only with respect to its pretreatment
level (Δday 1 − day 0 = −18.78 ± 3.92 mm Hg, P < .001) but also in
comparison with the control group (Δday 1 − day 0 = −4.27 ± 5.52 mm
Hg, P < .05; Figure 5B), which can also be visually confirmed in the
representative images (Figure 5C).
Histology Confirms MS 19F-MRI Assessment of an
Anti–VEGF-Induced Hypoxic Response
The reduction of pO2 in viable tumor in the B20.4.1.1 group was
attributed to the reduction of vessel density that was quantified by
MECA-32 staining (Figure 6A). Compared with the control group
(7.96 ± 0.76 mm−1), the B20.4.1.1-treated group exhibited a 40%
decrease in vessel density (4.76 ± 0.40 mm−1, P < .01; Figure 6B).
Consistent with the MRI pO2 results, tissue hypoxia measured by
hypoxyprobe staining showed that at 24 hours posttreatment, the
B20.4.1.1-treated group exhibited an increased hypoxic area fraction
(Figure 6C ) of approximately 13% [B20.4.1.1 (30.14 ± 2.78%) vs
control (17.11 ± 4.00%), P < .02; Figure 6D].
Dual PI3K/mTOR Inhibition Induces a Sustained Hypoxic
Response in Viable Tumor
In the second treatment study, PFCs remained in the tumor
throughout the course of the 4-day study following i.v. injection. No
significant loss of 19F signal was observed during the 4-day period
(Figure 7A), which enabled the longitudinal study of pO2 changes
over this time period. In general, both the B20.4.1.1- and GDC-
0980–treated groups showed decreased pO2 in viable tumor, relative
to pretreatment levels, following the onset of treatment. In the
B20.4.1.1-treated group, the pO2 values in viable tumor on day 1
(Δday 1 − day 0 = −13.26 ± 5.02 mm Hg), day 2 (Δday 2 − day 0 =
−10.31 ± 3.06 mm Hg), and day 3 (Δday 3 − day 0 = −12.67 ±
6.35 mm Hg) were all significantly lower than baseline at day 0 (P <
.05). When compared with the control group on day 1 (Δday 1 − day 0 =
−2.15 ± 5.12 mm Hg), day 2 (Δday 2 − day 0 = −3.55 ± 5.75 mm Hg),
and day 3 (Δday 3 − day 0 = −2.26 ± 5.33 mm Hg), the changes
in pO2 for the B20.4.1.1-treated group did not differ significantly
from the changes observed for the control group on any of the
3 days (P values were .14, .33, and .24 for days 1, 2, and 3, re-
spectively; Figure 7B). GDC-0980 had a strong effect for all
3 days after the onset of the treatment relative to its baseline at day 0
Figure 4. MS 19F-MRI–identified hypoxic regions in viable tumor
correlate with histology. (A) A one-to-one comparison between the
hypoxic area in viable tissue for the center slice of each tumor mea-
sured by MS 19F-MRI and pimonidazole-positive area in viable tissue
in the corresponding tumor slice measured by histology showed
a significant correlation. (B) The MRI hypoxia region was shown in
red, and the histologic hypoxia area was shown in brown. The
images showed similar patterns of hypoxia (pointed by arrows).
Figure 5. At 24 hours posttreatment, B20.4.1.1 exhibited a significant decrease in viable tumor pO2. (A) The B20.4.1.1-treated group showed
no significant change in viable tumor volume (NS, P> .05). (B) The viable tumor pO2was significantly reduced in the B20.4.1.1 group relative
to the pretreatment level (###P < .001) as well as in comparison with the control group (*P < .05). (C) Images showing pO2 change after
24 hours.
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Figure 6. At 24 hours posttreatment, B20.4.1.1 significantly decreased vascular density and increased hypoxic fraction in the viable tumor.
(A) Images show vessel density (brown, MECA-32 staining) at 24 hours posttreatment. Bar, 100 μm. (B) The B20.4.1.1 group showed a
40% reduction of vascular density in comparison with the control (**P< .01). (C) Images depict hypoxic cells (brown, hypoxyprobe staining)
at 24 hours posttreatment. Bar, 100 μm. (D) The B20.4.1.1 group showed a 13% increase in the hypoxic fraction in comparison with the
control (*P < .02).
Figure 7. (A) PFCs remained in the tumor throughout the course of the 4-day study following i.v. delivery. No significant loss of 19F signal
was observed, which enabled a multiday longitudinal study of pO2 change. Every effort was made to locate the same imaging slice in the
tumor according to the distance and shape, but deviations may still exist due to the positioning of the animal on different days, as well as
tumor growth. (B) The temporal evaluation of mean ΔpO2 in viable tumor. Both the B20.4.1.1 and GDC-0980 groups exhibited a decrease
in pO2 in the viable tumor posttreatment relative to pretreatment levels. When compared with the control group, the GDC-0980 group
exhibited a significant decrease in viable tumor pO2, whereas the B20.4.1.1 group showed a trend toward a reduction of pO2 (P = .14
on day 1). (C) The viable tumor volume change with time. Only the GDC-0980 group showed a significant reduction on day 3 in comparison
with the control. *P < .05 in comparison with the control group. #P < .05 versus pretreatment; ##P < .01 versus pretreatment. Data are
shown as means ± SEM.
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(Δday 1 − day 0 = −18.85 ± 5.24mmHg, P < .01;Δday 2 − day 0 = −26.16 ±
6.12 mm Hg, P < .01; Δday 2 − day 0 = −22.49 ± 6.72 mm Hg, P < .01;
Figure 7B). When compared with the control group, the GDC-0980
group exhibited a significant decrease in viable tumor pO2 (P < .05).
The significant decrease of pO2 in the GDC-0980 treatment group
occurred only in the viable tumor, whereas there were no significant
pO2 changes detected relative to control in any of the other tissue
classes (Figure W2). Similar to the first study, the B20.4.1.1-treated
group (Δday 1 − day 0 = 14.61 ± 2.94 mm
3, P > .05; Δday 2 − day 0 =
29.96 ± 9.58 mm3, P > .05; Δday 3 − day 0 = 36.86 ± 10.80 mm
3,
P > .05) did not exhibit a significant difference in viable tumor growth
when compared with control (Δday 1 − day 0 = 17.09 ± 3.25 mm
3,
Δday 2 − day 0 = 35.26 ± 5.60 mm
3, and Δday 3 − day 0 = 40.52 ±
7.58 mm3). Only the GDC-0980 group showed a significant reduc-
tion on day 3 in comparison with the control group (Δday 1 − day 0 =
24.11 ± 5.90 mm3, P > .05; Δday 2 − day 0 = 11.78 ± 14.64 mm
3,
P > .05; Δday 3 − day 0 = 0.26 ± 15.00 mm
3, P < .05; Figure 7C).
MS 19F-MRI Predicted Histologic Findings for Both
GDC-0980 and B20.4.1.1
The MRI pO2 results were further confirmed by histology (Fig-
ure 8A). Compared with the control group, the GDC-0980–treated
group exhibited a 20% increase in hypoxic fraction (P < .05), whereas
the B20.4.1.1-treated group showed no significant change in com-
parison with control (Figure 8B). The histologic staining further
revealed no significant change of vessel density between the B20.4.1.1-
treated group and the control group (P = .60), whereas a trend toward
reduction of vessel density in the GDC-0980-treated group (P = .066)
was observed (data not shown).
Discussion
This is the first study to employ a diffusion-based MS tissue segmenta-
tion approach to address the complications of tissue heterogeneity in
19F-MRI pO2 mapping. The validation study demonstrated that this
approach can detect tissue-dependent oxygenation changes in response
to a breathing gas challenge, and this in vivo technique showed a
good correlation with histologic estimates of hypoxia. The results from
the treatment studies to assess the effects of two antivascular agents on
tumor oxygenation demonstrated a rapid reduction in viable tumor
pO2 after treatment. Dual PI3K/mTOR inhibition by GDC-0980
strongly suppresses tumor oxygenation consistent with the known anti-
vascular response for this molecule [17]. Anti-VEGF treatment signifi-
cantly lowered viable tumor pO2 relative to control in the first study
but did not achieve statistical significance in the second study. In both
treatment studies, in vivo MS 19F-MRI pO2 estimates predicted the
histologic hypoxia results. These results advocate for the use of this
MS 19F-MRI technique as a tool to better understand the mode of
action of therapies that alter the tumor’s microenvironment.
Different PFCs have been used for in vivo oxygenation studies
[10]. The perfluoro-15-crown-5-ether employed in this study as an
imaging contrast agent has two major advantages over other PFCs:
its sensitivity for measuring small changes in pO2 [4] and a lack of
tissue toxicity [25]. The R1 parameter for the PFC contrast agent was
measured to obtain pO2 estimates. Consistent with previously pub-
lish studies, the R1 relaxation rate of perfluoro-15-crown-5-ether is a
linear function of oxygen level (R2 = 0.999) at 37°C at 9.4 T
[4,7,25]. While the pO2 measured in the current study is similar to
some previous studies [4,7], differences do exist with pO2 values mea-
sured under different settings in other studies [26,27]. These differ-
ences may be due to the fact that pO2 values have been shown to vary
with tumor cell line, tumor size, and tissue heterogeneity [27,28], as well
as the methodology that was used for measurements [6]. In addition,
the method of PFC administration may affect the relative spatial PFC
distribution. Although i.v. injection gives a more global measurement
when compared with local PFC injection directly into the tumor, i.v.
delivery of PFCs may bias pO2 estimates toward well-perfused areas
and regions close to the blood vessels [29]. In the current studies, PFCs
were administrated before treatments, when the tumors were highly
vascularized, and this resulted in the PFCs being delivered and retained
in the tumor at a sufficient level to make reliable pO2 measurements
throughout the study. Thus, any induced hypoxia due to treatment or
tumor growth that occurs after PFCs were administrated could be accu-
rately measured because the PFCs are already present in the tumor.
In this study, tumor heterogeneity is addressed by employing
diffusion-based MS analysis to differentiate distinct tissue classes. A
reproducibility study was performed by assessing the consistency of
the pO2 estimates for the four tissue classes from two repetitive mea-
surements made under normoxic conditions. The class estimates were
found not to differ significantly, demonstrating the reproducibility of
the technique. It is worth noting that although there is no statistical
difference between the two measurements, the two pO2 maps were
not fully identical on a voxel-by-voxel basis. These apparent voxel dif-
ferences could be due to local acute hypoxic fluctuations that have
been observed in tumors [30,31]. The current method, however,
cannot fully resolve these transient changes in pO2 due to its low tem-
poral resolution. Apart from these physiological factors, the system and
measurement noise could also contribute to specific voxel differences.
Different tissue responses were observed during the hyperoxia
challenge experiment, which provides further support for this MS
approach. The viable tumor and subcutaneous adipose tissue are
well-vascularized tissues and, thus, respond actively to the hyperoxia
challenge. The low-T 2 necrosis class exhibited an increase in pO2 on
Figure 8. At 72 hours posttreatment, GDC-0980 significantly
increased the hypoxic fraction in viable tumor as assessed by his-
tology. (A) Images showed hypoxic cells at 72 hours posttreatment.
Bar, 300 μm. (B) GDC-0980 showed a significant increase in hypoxic
fraction (*P < .05), whereas the B20.4.1.1-treated group showed
no significant change (P > .05).
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breathing gas challenge. This could be due to several possible mecha-
nisms that include the following: Circulating RBCs with an increased
oxygen load may have entered the region due to active hemorrhage.
Another possibility is that there may have been an increase in oxygen
diffusing from the neighboring viable tissue. In addition, partial volume
contamination from neighboring viable tissue may have contributed
to the response. The high-ADC necrosis class did not show a signifi-
cant change in pO2, which is consistent with its acellular cyst-like
nature [12], although the presence of an apparent trend in the data
may be due to partial volume influence from neighboring viable tissue.
The differing sensitivity in response to the gas challenge among the
four tissue classes is likely due to the difference in pathophysiological
features of these tissue classes that have been previously characterized
[12,20,21]. These results indicate that the inclusion of nonviable
tumor tissue regions in whole-tumor estimates of pO2 response can
mask or bias the changes of pO2 within the tissue of therapeutic in-
terest (viable tumor) depending on the relative volume ratio of each
tissue class. Restricting the analysis of tumor oxygenation to the viable
tumor is physiologically meaningful and could aid investigations of
therapeutic responses.
The MS 19F-MRI approach to assessing pO2 within viable tumor
was applied to serially monitor the effects of antivascular therapies
on tumor oxygenation. Two treatments were used in this study, an
anti-VEGF molecule (B20.4.1.1) and a dual PI3K/mTOR inhibitor
(GDC-0980). The effect of antivascular agents on tumor oxygenation
has been in question for a number of years. Some studies have shown
increased tumor hypoxia after anti-VEGF treatment [13,15,16],
whereas other studies show decreased tumor hypoxia (increased pO2)
[14,32,33]. These different observations may be explained in part
by the role of vessel normalization in the response of tumors to anti-
angiogenic therapy where antiangiogenic therapies initially improve
both the structure and the function of tumor vessels, whereas sus-
tained or more aggressive antiangiogenic regimens eventually prune
away functional vessels resulting in a more hypoxic environment [34].
In the current studies, anti-VEGF (B20.4.1.1) treatment did not cause
an increase in viable tumor pO2. This may be due to the strong anti-
vascular response caused by a 10 mg/kg dose of B20.4.1.1, resulting
in a very short or the complete absence of a transient normalization
window occurring after treatment. These results are consistent with
previous findings where B20.4.1.1 was shown to reduce vascular den-
sity and inhibit tumor growth [17,35]. Although no evidence of an
increase of pO2 was observed in the current studies, the possibility of
a pO2 increase at earlier time points cannot be ruled out. The differ-
ence in pO2 response by B20.4.1.1 treatment between the two treat-
ment studies was likely due to the lack of statistical power. However,
in both studies, the in vivo MRI pO2 measurements predicted the
ex vivo histologic results of hypoxic fraction for B20.4.1.1 treatment
response relative to control. The other treatment that was evaluated,
GDC-0980, a novel dual inhibitor of mTOR and PI3K, exhibited a
significant decrease in viable tumor pO2 (P < .05). Ex vivo histologic
measurements of hypoxic fraction confirmed a significant increase
in hypoxic fraction of the GDC-0980–treated tumors. The strong
suppression of pO2 induced by GDC-0980 is likely because of the
suppression of oxygen supply due to the loss of small functional vessels
as previously demonstrated [17]. In addition, compared to B20.4.1.1,
an anti–VEGF-A monotherapy, GDC-0980 treatment resulted in
greater tumor growth inhibition due to both PI3K pathway inhibition
in the tumor cells and a strong antivascular effect [17]. It is also im-
portant to note that among the four tissue classes, viable tumor was
the only class where GDC-0980 produced a statistically significant
decrease in pO2 relative to the changes observed in the control group
(Figure W2). This supports the notion that, depending on the relative
volume ratio of each tissue class, the inclusion of nonviable tumor
tissue regions in whole-tumor estimates of pO2 response can mask
or bias the changes of pO2 within the tissue of therapeutic interest
(viable tumor). Furthermore, targeting hypoxia in tumors has been a
great interest to the field of combination therapies [2,11,36]. In this
sense, MS 19F-MRI may provide a valuable tool for research efforts into
combination therapies that target the altered microenvironment.
In conclusion, this work has demonstrated for the first time that
pO2 measurements can be restricted to the viable tumor and that the
necrotic tissue classes contribute erroneous data to whole-tumor esti-
mates of the pO2 response. The MS
19F-MRI approach provides a
means to measure pO2 within the viable tumor and address the issue
of tumor heterogeneity that complicates pO2 tumor imaging. In addi-
tion, this methodology has been employed to better understand the
effects of antivascular agents on tumor oxygenation. Detected by MS
19F-MRI, a potent and selective PI3K/mTOR inhibitor showed strong
suppression of tumor oxygenation for the first time. These results
advocate for the use of the MS 19F-MRI technique as a tool to better
understand the mode of action of therapies that alter the tumor’s
microenvironment and may provide insight into combination therapies
that target the altered microenvironment.
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Figure W1. The linear relationship between the R1 of perfluoro-
15-crown-5-ether and the oxygen level. The cartoon depicts the
structure of the PFC emulsions that contain perfluoro-15-crown-5-
ether (green) and a lipid bilayer (pink). Twenty-one percent of oxygen
corresponds to 160 mm Hg, and 100% of oxygen corresponds to
760 mm Hg.
Figure W2. At 72 hours posttreatment, GDC-0980 significantly
decreased pO2 in the viable tumor but not in the other tissue classes
when compared with the control group (*P < .05), whereas the
B20.4.1.1-treated group showed no significant differences relative
to the control (P > .05). #P < .05 versus pretreatment; ##P < .01
versus pretreatment level.
